Total Payments
$111,968
2024 Payments
$1,937
Companies
43
Transactions
707
Medicare Patients
6,703
Medicare Billing
$1.5M
Payment Breakdown by Category
Other$86,714 (77.4%)
Food & Beverage$10,244 (9.1%)
Research$10,195 (9.1%)
Travel$4,513 (4.0%)
Education$274.40 (0.2%)
Gifts$27.28 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $86,500 | 41 | 77.3% |
| Food and Beverage | $10,244 | 620 | 9.1% |
| Unspecified | $10,195 | 10 | 9.1% |
| Travel and Lodging | $4,513 | 29 | 4.0% |
| Education | $274.40 | 4 | 0.2% |
| Entertainment | $213.94 | 1 | 0.2% |
| Gift | $27.28 | 2 | 0.0% |
Payments by Type
General
$101,773
697 transactions
Research
$10,195
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $91,773 | 118 | $0 (2020) |
| Eli Lilly and Company | $10,195 | 10 | $0 (2021) |
| ABBVIE INC. | $1,807 | 118 | $0 (2024) |
| Janssen Biotech, Inc. | $1,344 | 81 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,068 | 65 | $0 (2024) |
| IRONWOOD PHARMACEUTICALS, INC | $889.94 | 59 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $655.60 | 42 | $0 (2024) |
| Romark Laboratories, LC | $530.14 | 18 | $0 (2020) |
| Celgene Corporation | $365.58 | 24 | $0 (2024) |
| Ardelyx, Inc. | $326.40 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,937 | 102 | ABBVIE INC. ($413.29) |
| 2023 | $1,690 | 104 | ABBVIE INC. ($378.87) |
| 2022 | $1,388 | 90 | ABBVIE INC. ($360.06) |
| 2021 | $1,977 | 82 | Eli Lilly and Company ($514.69) |
| 2020 | $5,958 | 55 | Eli Lilly and Company ($2,681) |
| 2019 | $50,391 | 100 | Allergan Inc. ($43,450) |
| 2018 | $43,196 | 103 | Allergan Inc. ($41,502) |
| 2017 | $5,431 | 71 | Allergan Inc. ($4,282) |
All Payment Transactions
707 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.73 | General |
| Category: Gastroenterology | ||||||
| 12/19/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/12/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/10/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/05/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $4.35 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $28.01 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: LIVER DISEASE | ||||||
| 12/03/2024 | ABBVIE INC. | SKYRIZI (Biological) | Education | In-kind items and services | $8.45 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: Gastroenterology | ||||||
| 12/02/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.72 | General |
| 11/25/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $9.88 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/21/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $23.91 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/21/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/20/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: VIROLOGY | ||||||
| 11/20/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/19/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $33.25 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $4.30 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/18/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $12.37 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.68 | General |
| Category: Immunology | ||||||
| 11/07/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.26 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: Immunology | ||||||
| 11/05/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $20.41 | General |
| Category: Gastroenterology | ||||||
| 10/30/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: LIVER DISEASE | ||||||
| 10/28/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: Gastroenterology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $4,293 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $3,603 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $1,552 | 1 |
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $747.27 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 1,516 | 22,395 | $931,695 | $431,321 |
| 2022 | 26 | 1,518 | 14,745 | $786,736 | $314,484 |
| 2021 | 28 | 1,855 | 17,579 | $937,265 | $359,775 |
| 2020 | 26 | 1,814 | 18,075 | $900,276 | $366,236 |
Total Patients
6,703
Total Services
72,794
Medicare Billing
$1.5M
Procedure Codes
104
All Medicare Procedures & Services
104 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 25 | 12,900 | $322,500 | $223,698 | 69.4% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 20 | 2,160 | $108,000 | $50,293 | 46.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 342 | 447 | $62,580 | $37,846 | 60.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 139 | 140 | $114,100 | $24,967 | 21.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 185 | 185 | $34,654 | $17,896 | 51.6% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 75 | 412 | $22,660 | $14,632 | 64.6% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 75 | 240 | $18,000 | $11,311 | 62.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 51 | 83 | $17,430 | $7,448 | 42.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 118 | 123 | $55,350 | $5,578 | 10.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 56 | 57 | $8,835 | $5,554 | 62.9% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 56 | 60 | $64,400 | $5,460 | 8.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 71 | 72 | $49,320 | $5,333 | 10.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 43 | 68 | $5,780 | $4,009 | 69.4% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 25 | 25 | $7,362 | $3,602 | 48.9% |
| 46945 | Tying of single internal hemorrhoid group | Facility | 2023 | 11 | 11 | $4,400 | $2,773 | 63.0% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 16 | 16 | $9,280 | $2,595 | 28.0% |
| 74170 | Ct scan of abdomen before and after contrast | Office | 2023 | 18 | 21 | $4,546 | $2,335 | 51.4% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 17 | 17 | $9,860 | $2,115 | 21.5% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 14 | 15 | $5,775 | $1,239 | 21.4% |
| 76705 | Limited ultrasound scan of abdomen | Office | 2023 | 32 | 33 | $2,178 | $1,120 | 51.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 13 | $1,300 | $688.55 | 53.0% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 49 | 5,200 | $2,600 | $588.81 | 22.6% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 15 | 15 | $375.00 | $202.50 | 54.0% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 50 | 82 | $410.00 | $39.17 | 9.6% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2022 | 14 | 6,000 | $150,000 | $103,416 | 68.9% |
About Dr. Paul Lamb, MD
Dr. Paul Lamb, MD is a Gastroenterology healthcare provider based in Dothan, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1386769404.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Lamb, MD has received a total of $111,968 in payments from pharmaceutical and medical device companies, with $1,937 received in 2024. These payments were reported across 707 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($86,500).
As a Medicare-enrolled provider, Lamb has provided services to 6,703 Medicare beneficiaries, totaling 72,794 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 104 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology
- Location Dothan, AL
- Active Since 03/20/2007
- Last Updated 02/18/2020
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1386769404
Products in Payments
- LINZESS (Drug) $69,181
- ZENPEP (Drug) $22,537
- STELARA (Biological) $1,174
- VIBERZI (Drug) $947.71
- TRULANCE (Drug) $658.16
- Linzess (Drug) $442.87
- ENTYVIO (Biological) $414.43
- XIFAXAN (Drug) $388.20
- Alinia Tablets 500mg 30 count bottle (Drug) $385.20
- ZEPOSIA (Drug) $349.84
- DUPIXENT (Biological) $347.52
- IBSRELA (Drug) $326.40
- RINVOQ (Biological) $298.76
- HUMIRA (Biological) $289.10
- SKYRIZI (Biological) $282.15
- Humira (Biological) $197.23
- OCALIVA (Drug) $189.75
- CREON (Drug) $185.09
- REMICADE (Biological) $165.78
- INJECTAFER (Drug) $161.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Dothan
Mr. Travis Rutland, Md, MD
Gastroenterology — Payments: $265,022
Gastroenterology $265,022
Scott Sarrels, M.d, M.D
Gastroenterology — Payments: $15,718
Gastroenterology $15,718
Samuel Tarwater, Md, MD
Gastroenterology — Payments: $15,397
Gastroenterology $15,397
William Mclaughlin, Md, MD
Gastroenterology — Payments: $9,913
Gastroenterology $9,913
George Nelson, M.d, M.D
Gastroenterology — Payments: $8,417
Gastroenterology $8,417
Jeffrey Crittenden, Md, MD
Gastroenterology — Payments: $8,300
Gastroenterology $8,300